Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low

Journal of Infectious Diseases

Volumn 176, Issue 1, 1997, Pages 304-307

  Stelma, Foekje F ^a   Sall, Souleymane ^b   Daff, Bocar ^b   Sow, Seydou ^b   Niang, Malick ^b   Gryseels, Bruno ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

OXAMNIQUINE; PRAZIQUANTEL;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; ENDEMIC DISEASE; EPIDEMIC; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARASITE IDENTIFICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SENEGAL;

EID: 0030941388     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517273     Document Type: Article

References (14)

1. Davies A. Antischistosomal drugs and clinical practice. In: Jordan P, Webbe G, Sturrock RF. Human schistosomiasis. Wallingford, CT: CAB International, 1993:367-404.
2. Stelma FF, Talla I, Sow S, et al. Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am J Trop Med Hyg 1995;53:167-70.
3. Stelma FF, Talla I, Polman K, et al. Epidemiology of Schistosoma mansoni infection in a recently exposed community in Northern Senegal. Am J Trop Med Hyg 1993;49:701-6.
4. Brindley PJ, Sher A. The chemotherapeutic effect of praziquantel against Schistosoma mansoni is dependent on host antibody response. J Immunol 1987;139:215-20.
5. Fallon PG, Sturrock RF, Capron A, Niang M, Doenhoff MJ. Short report: diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am J Trop Med Hyg 1995;53:61-2.
6. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo 1972;14:397-400.
7. Gryseels B, Stelma FF, Talla I, et al. Epidemiology, immunology and chemotherapy of Schistosoma mansoni infections in a recently exposed community in Senegal. Trop Geogr Med 1994;46:209-19.
8. Gryseels B. Praziquantel in Senegal Schistosomiasis outbreak. Trop Dis Res News 1993;42:10-2.
9. Cioli D, Pica-Mattoccia L, Archer S. Drug resistance in schistosomes. Parasitol Today 1993;9:162-6.
10. Fallen PG, Doenhoff MJ. Drug-resistant Schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am J Trop Med Hyg 1994;51:83-8.
11. Gryseels B, Nkulikyinka L, Coosemans MH. Field trials of praziquantel and oxamniquine for the treatment of Schistosomiasis mansoni in Burundi. Trans R Soc Trop Med Hyg 1987;81:641-4.
12. Polderman AM, Gryseels B, De Caluwé P. Cure rates and egg reduction in treatment of intestinal schistosomiasis with oxamniquine and praziquantel in Maniema, Zaire. Trans R Soc Trop Med Hyg 1988;82:115-6.
13. Sabah AA, Fletcher C, Webbe G, Doenhoff MJ. Schistosoma mansoni: chemotherapy of infections of different ages. Exp Parasitol 1986;61:294-303.
14. Shaw MK, Erasmus DA. Schistosoma mansoni: The effects of a subcurative dose of praziquantel on the ultrastructure of worms in vivo. Zentralbl Parasitenkd 1983;69:73-90.